55 results about "Conducting system" patented technology

Transcatheter aortic valve prostheses for improving the cardiac function of a patient suffering from coronary artery disease. Transcatheter aortic valve prostheses include a valve component and a frame. The valve component includes valve leaflets and a skirt. The frame includes access cells that improve access to a patient's coronary arteries if further intervention is required and / or includes a window or conduction protection cell that is oriented to align with a portion of conduction system of the heart in situ to reduce conduction disturbances of the anatomy. Suture patterns for attaching a commissure to a commissure post of the frame, and for attaching a tissue bumper to the commissure post, are also described.

An implantable lead for use with an implantable medical device (IMD) includes a tubular lead body having a proximal portion including a proximal end, a distal portion including a distal end opposite the proximal end, and an intermediate portion between the proximal portion and the distal portion. A helical electrode extends distally from the distal end of the tubular lead body. At least one atrial electrode is disposed in the intermediate portion of the tubular lead body. At least one electrical conductor extends through the tubular lead body and is mechanically and electrically coupled to the helical electrode and the at least one atrial electrode. The intermediate portion may have a pre-formed bend configured to urge the at least one atrial electrode against a surface of the right atrium when the lead is implanted. A distal pre-formed bend located in the distal portion of the tubular lead body may be configured to bias a plurality of pacing / sensing electrodes towards a surface of a right ventricle. A distal pre-formed bend located in the distal portion of the tubular lead body may be configured to bias the helical electrode and at least one pacing / sensing against a surface of a right ventricle.

A medical device system includes a memory configured to store cardiac signals sensed after delivery of ventricular conduction system pacing pulses. The medical device system includes processing circuitry configured to determine a capture type classification of the ventricular conduction system pacing pulses, and generate an output based on the capture type classification. The medical device system may include a user interface configured to present a representation of the capture type classification associated with the delivered ventricular conduction system pacing pulses.

A medical device is configured to receive a conduction system pacing therapy command which may correspond to one of a first conduction system pacing therapy command or a second conduction system pacing therapy command. The medical device may determine an atrioventricular (AV) pacing interval according to a first method in response to receiving the first conduction system pacing therapy command. The medical device may determine the AV pacing interval according to a second method different than the first method in response to receiving the second conduction system pacing therapy command. The medical device may schedule conduction system pacing pulses for delivery at the determined AV pacing interval.

A medical device is configured to deliver His-Purkinje pacing pulses according to multiple settings of a pacing control parameter and determine an electromechanical time delay from a ventricular electrical event to a fiducial point of the pressure signal for each of the pacing control parameter settings. The medical device may be configured to select an operating pacing control parameter from the pacing control parameter settings based on a determined electromechanical time delay being less than a threshold interval. The medical device may deliver pacing pulses to the His-Purkinje conduction system according to the selected operating pacing control parameter.

In some examples, a method comprises sensing one or more left-ventricular activations via one or more electrodes of a left-ventricular lead, wherein each of the one or more left-ventricular activations are in response to delivery of an electrical stimulation to a heart of a patient; determining one or more left-ventricular activation metrics based on the sensed one or more left-ventricular activations; and determining whether the electrical stimulation provided conduction system pacing based on the one or more ventricular activation metrics.

The present invention discloses a heart valve stent and prosthesis thereof. The stent comprises a stent frame comprising a plurality of interconnected grids, with multiple end grids at both ends of the stent frame, at least one of which is a first end grid. All end grids at the end where the first end grid is located are continuously and completely distributed in the circumferential direction, and the axial projection height of the first end grid is lower than the axial projection heights of the other end grids at the same end. The heart valve stent and prosthesis provided by the present invention can reduce damage to the conduction system and reduce conduction block, thereby improving surgical safety and the patient's quality of life.

Antitachycardia pacing (ATP) therapy may be delivered to the cardiac conduction system using cardiac conduction system pacing therapy. An initial cardiac conduction system ATP pulse set including three or less cardiac conduction system ATP pulses may be delivered to the patient's cardiac conduction system. A first cardiac conduction system ATP pulse of the initial cardiac conduction system ATP pulse set may be delivered at an interval configured to provide maximal capture of the cardiac conduction system.

An implantable medical device includes a plurality of implantable electrodes for sensing and pacing a heart of a patient. The plurality of electrodes includes cardiac conduction system electrodes positionable proximate a portion of a cardiac conduction system of a patient. A computing device includes processing circuitry and is operably coupled to a plurality of implantable electrodes. A computing device monitors a precardiac ejection (HS-PEP) of a heart of a patient. A change in the HS-PEP is determined based on the monitoring. A change in HS-PEP is determined to be greater than or equal to a specified threshold. Delivery of cardiac conduction system pacing therapy to the cardiac conduction system of the patient using the cardiac conduction system electrode is initiated based on the HS-PEP being greater than or equal to a specified threshold.

A blood treatment device for extracorporeal blood treatment and a method for monitoring the fill level of blood with the blood treatment device. The device includes at least one blood conducting system and at least one chamber container for separating bubbles from the blood to be treated. The device further includes a blood pumping device designed to pump the blood and generate pressure pulses with a predefined frequency in the blood conducting system. The blood treatment device additionally has at least one pressure detection sensor for capturing the pressure pulse introduced by the blood pumping device and a data processing unit designed to derive a fill level parameter from the pressure pulse captured and to modify the state of an information signal as a function of the fill level parameter. At least one alarm device is activated as a function of the state of the information signal.

A medical device system includes a sensing circuit configured to sense at least one cardiac electrical signal, a therapy delivery circuit configured to deliver conduction system pacing pulses for capturing at least a portion of the cardiac conduction system and a memory configured to store a start time and an end time of a template window. The medical device system includes processing circuitry configured to acquire from the at least one cardiac electrical signal a first post-pace waveform extending over the template window and establish a template using at least the first post-pace waveform. The processing circuitry may acquire from the at least one cardiac electrical signal a second post-pace waveform extending over the template window and determine at least one morphology match score from the template and the second post-pace waveform.

A medical device system includes a memory configured to store a cardiac signal sensed following delivery of a ventricular conduction system pacing pulse. The medical device system includes processing circuitry configured to determine a capture type classification of the ventricular conduction system pacing pulse and generate an output based on the capture type classification. The medical device system may include a user interface configured to present a representation of the capture type classification associated with the delivered ventricular conduction system pacing pulse.

This article describes systems and methods for determining whether cardiac conduction system pacing therapy may be beneficial and / or for determining how close or far a cardiac conduction system block may be using external cardiac signals. For this purpose, one or more left-sided measures can be generated based on left-sided alternative cardiac electrical activity measured using multiple left external electrodes to produce information on electrical heterogeneity.

An implantable medical device includes processing circuitry, the computing apparatus configured to communicate with a plurality of implantable electrodes to sense and pace a patient's heart. The plurality of electrodes include a conduction system pacing electrode positioned in a myocardium of the patient's heart. The computing apparatus is configured to monitor local muscle impedance of the patient's heart using the cardiac conduction system electrode and adapt cardiac therapy deliverable by the implantable device based on the local muscle impedance.

A system includes a medical device including therapy delivery circuitry configured to deliver conduction system pacing to a heart of a patient via a first one or more of a plurality of electrodes disposed on an implantable medical lead coupled to the medical device and deliver anodal stimulation pacing via a second one or more of the plurality of electrodes disposed on the implantable medical lead; and sensing circuitry configured to sense one or more cardiac electrograms (EGMs) of the patient responsive to the delivery of the anodal stimulation pacing; and processing circuitry configured to: control the delivery of the anodal stimulation pacing by the therapy delivery circuitry on a periodic schedule; determine the implantable medical lead has migrated based on the one or more cardiac EGMs; and output an alert indicating the implantable medical lead has migrated to a user.

The present invention is related to an occlusion device for occluding an opening in a body tissue and a method of deploying said occlusion device to the site of defect. The occlusion device comprises a flexible proximal high-pressure disc and a flexible distal low-pressure disc, that are centrally connected by a central connector section of varying diameter and length which further comprises a stretchable narrow connector at the tapered end, and retention screws. The design of the occlusion device of the present invention is such that it enables haemodynamic adjustment providing a better-fit to the size of the defect, and reduction of clamping force and stress on the conduction system.

Illustrative systems, devices, and methods monitor cardiac morphology during delivery of cardiac conduction system pacing therapy to determine effective cardiac conduction system pacing therapy. If effective cardiac conduction system pacing therapy is not determined, one or both of the cardiac conduction system pacing vector and atrioventricular delay may be adjusted until the monitored cardiac morphology indicates effective cardiac conduction system pacing therapy.

An adaptive cardiac conduction system pacing therapy may monitor electrical activity of a patient's heart and select a cardiac conduction system pacing therapy pacing pattern based on the monitored electrical activity. For example, one or more metrics, such as a P-wave to R-wave interval and a QRS complex wave width, may be determined based on monitored electrical activity, and one of a suppression pacing mode, a ventricular fusion pacing mode, an atrioventricular synchronization pacing mode, and an atrial fibrillation pacing mode may be selected based on the determined one or more metrics.

Leadless ventricular pacemaker devices are provided along with systems and methods for using them. In one example, the device includes an elongated member configured to be advanced through a tubular member into a patient's heart; a conformational change mechanism configured to reconfigure the elongated member from an elongated shape to a folded state upon exiting the tubular member; and. a plurality of electrodes on the elongated member and configured to deliver unipolar or bipolar pacing to tissue within the patient's heart, wherein the device is configured to be implanted into a septum of a right ventricle within or adjacent to a native conduction system of the patient's heart.

A medical device system configured to obtain a cardiac electrical signal seizure sensed during a conduction system capture management test, and determine capture test data from the cardiac electrical signal seizure. The medical device system may be configured to: detect an alarm condition of the conductive system capture management test, the alarm condition indicating a change in the capture test data compared to a previous conductive system capture management test; and generating an output in response to detecting the alarm condition. The generated output may be stored in a memory of the medical device system. The medical device system may display data in a user interface based on the generated output.

A method of operating a cardiac rhythm management (CRM) system includes: measuring a baseline PR interval of cardiac depolarization; measuring one or both of the heart sound and the heart depolarized QRS width; delivering pacing stimulation according to atrial sensing of a ventricular pacing interval (AsVp interval), and measuring one or both of a heart sound and a QRS width of the AsVp interval, where the pacing stimulation is delivered using a conducted system pacing (CSP) vector comprising electrodes positioned in the interventricular septum; delivering a pacing stimulus according to an atrial pacing to ventricular pacing interval (ApVp interval) and measuring one or both of a heart sound and a QRS width of the ApVp interval; and generating a recommended atrial-to-ventricular delay setting for the CSP based on one or both of the measured heart sound and the QRS width.

In some examples, a method comprises sensing one or more left-ventricular activations via one or more electrodes of a left-ventricular lead, wherein each of the one or more left-ventricular activations are in response to delivery of an electrical stimulation to a heart of a patient; determining one or more left-ventricular activation metrics based on the sensed one or more left-ventricular activations; and determining whether the electrical stimulation provided conduction system pacing based on the one or more ventricular activation metrics.

Described herein are systems, methods, and apparatuses for determining capture of a cardiac conduction system by a ventricular to atrial (VfA) therapy. A VfA therapy can be delivered at a plurality of different A-V delays while the electrical activity of a patient is monitored. The electrical activity can then be utilized to determine whether the cardiac conduction system of the patient has been captured by the VfA therapy.

An implantable lead for use with an implantable medical device (IMD) includes a tubular lead body having proximal end and a distal end opposite the proximal end. A proximal connector is located at the proximal end of the lead body and is configured for mechanically and electrically coupling the lead to the IMD. The lead includes a pre-formed distal portion having a first portion extending from the distal end to a first curve. The first portion is located in a first plane. A second portion extends from the first curve to a second curve, wherein the second portion and the second curve are located in a second plane that is generally orthogonal to the first plane. A helical electrode extends distally from the distal end of the tubular lead body and a ring electrode is located along the first portion.

An implantable medical system includes an implantable catheter advanceable into a coronary sinus of a patient's heart. A guide element and an implantable lead receivable in the side lumen is advanceable through an angled opening of the catheter to be deflected laterally away from the catheter at the deflection angle to position the at least one testing electrode or at least one pacing electrode, respectively, in a myocardium of the patient's heart when the distal portion of the catheter is positioned in the coronary sinus.

Antibodies which bind selectively to cardiac conduction system (CCS) cells, imaging and / or diagnostic reagents and compositions visualizing the CCS cells and therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention. Compositions and methods for isolation, purification, analyses and / or transplantation of the CCS cells, including pluripotent stem cell (hiPSC)-derived or human embryonic stem cell (hESC)-derived CCS cells.

The invention provides a simulated jellyfish-based plateau environment systolic function model, which comprises a jellyfish-shaped framework and a cardiac muscle tissue layer cultured on the jellyfish-shaped framework, and is used for simulating the systolic function of the heart through spontaneous or rhythmic systole; the pacing point and conduction system consists of a patterned myocardial cell layer and is used for generating and / or conducting an electric signal to stimulate rhythmic contraction / relaxation of a myocardial tissue layer; the balance weight is arranged at the bottom of the center of the jellyfish-shaped frame and used for enabling the gravity borne by the simulated jellyfish in the culture solution to be larger than the buoyancy borne by the simulated jellyfish. The invention also provides a simulated jellyfish-based plateau environment systolic function simulation and detection system, and the simulated jellyfish-based plateau environment systolic function model is used as a bionic simulator and is used for analyzing the motion state, tissue pathology and metabolism conditions of the bionic simulator in a body blood component culture solution in a simulated plateau environment. And evaluating the influence of the culture solution on the heart function.

A method of renovating a liquid-conducting system (2, 3) comprises providing a liner (41, 42), applying the liner (41, 42) to at least a wall portion (20, 31, 32, 33) of the liquid-conducting system, and causing the liner (41, 42) to conform to a wall portion shape. The method further comprises applying an adhesive sealing sheet (100, 100', 100", 110, 110', 110") to at least a portion of the wall portion (20, 31, 32, 33) of the liquid-conducting system, such that a first adhesive surface (S1) of the adhesive sealing sheet (100, 100', 100", 110, 110', 110") causes the adhesive sealing sheet to adhere to the wall portion (20, 31, 32, 33). The adhesive sealing sheet (100, 10 100', 100", 110, 110', 110") is arranged between the wall portion (20, 31, 32, 33) and the liner (41, 42).

The invention relates to the technical field of scoliosis correction, in particular to an in-vitro confrontation type scoliosis correction system which comprises a system framework and an intelligent control system, and the system framework is composed of a double-track confrontation support, an intelligent push plate assembly and a mechanical conduction system; the body surface of a patient is scanned through the optical body surface scanning module to generate a reference three-dimensional coordinate, and the arc-shaped self-adaptive push plate is adjusted through the multi-degree-of-freedom adjusting mechanism, so that the arc-shaped self-adaptive push plate can be automatically corrected according to parameters. An arc-shaped self-adaptive push plate utilizes a bionic pressure diffusion technology to carry out a pressure distribution automatic optimization algorithm, so that the local pressure intensity is prevented from being too high, an intelligent control system is adopted to control an intelligent push plate assembly to carry out correction, a mechanical correction report can be generated after an operation, a subsequent treatment scheme can obtain relatively sufficient data support, and the operation efficiency is improved. For different patients, reasonable treatment schemes and correction parameters can be given, and accurate control over in-vitro confrontation correction is achieved.

The invention discloses a hot compress medicine guiding system and method. The method comprises the following steps that S1, the type of a medicine bag is determined; s2, initial parameters are set, specifically, the monitoring range of a concentration monitoring unit and the heating temperature and working time of a heating unit are set according to the medicine bag type determined in S1; s3, selecting a heat transfer mode: determining to use heat conduction or heat radiation to transfer heat based on the wearing position of the medicine bag; and S4, monitoring the drug concentration in real time and adjusting the temperature: continuously monitoring the drug concentration through a concentration monitoring unit, and dynamically adjusting the temperature of a heating unit by a control unit according to a concentration monitoring result so as to maintain the drug concentration within a set range. The device is simple in structure, can continuously act on a drug needing transdermal delivery at a specific temperature for several hours, and automatically adjusts the temperature by identifying the drug concentration, so that the transdermal delivery absorption rate is greatly improved, and a continuous and effective transdermal delivery closed loop is formed.